ArticleDiabetology international2026
Identification and validation of tolerogenic dendritic cells-related biomarkers in diabetic retinopathy.
Article in Diabetology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic retinopathy (DR) is a primary microvascular complication of diabetes. Its pathogenesis is associated with chronic inflammation and immune responses. While tolerogenic dendritic cells (tolDCs) are critical for suppressing excessive inflammation and maintaining immune homeostasis, their function in DR is not well characterized. Objective: To identify biomarkers associated with tolDCs in DR and to explore their mechanisms. Methods: Biomarkers were identified from public databases using differential analysis, machine learning (LASSO regression analysis and Random Forest analysis), and expression validation. Their mechanisms were then explored through enrichment analysis and immune infiltration, and ultimately validated by reverse transcription-quantitative PCR (RT-qPCR) on clinical blood samples. Results: A total of 2096 differentially expressed genes (DEGs)1 were identified between DR and control groups. By intersecting with 6267 tolDCs-related genes, 51 key candidates were selected. Machine learning and expression validation further pinpointed two biomarkers: transcription factor EC (TFEC) and chromatin modifying protein 2 A (CHMP2A). Gene Set Enrichment Analysis (GSEA) showed significant enrichment of TFEC in 994 pathways and CHMP2A in 748, with co-enriched pathways including apoptosis, VEGFA-VEGFR2 signaling, and VEGF signaling. Analysis identified eight altered immune cell types; TFEC correlated strongest with activated NK cells (cor = - 0.49, Conclusion: TFEC and CHMP2A are potential biomarkers involved in DR pathogenesis via tolDCs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.